γδ T Cell Cancer Immunotherapy: Evidence-Based Perspectives for Clinical Translation (Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy) - Tapa dura

Acerca del autor

Dr. Marta Barisa is a Senior Fellow in Experimental Oncology at University College London (UCL). She is based at the Cancer Section of UCL’s Zayed Centre of the Great Ormond Street Institute of Child Health.

She completed her undergraduate degree at St. George’s Hospital Medical School in London, UK, followed by training in molecular immunology and cellular immunotherapy at UCL, as well as the Massachusetts Institute of Technology in Boston, USA. Most of her career has focused on immunotherapy drug development for various oncology indications ― alone or in combination with additional immunotherapeutic, radio- and chemotherapeutic interventions.

For much of her research career she has been based at UCL, which is a world-leading centre for cellular immunotherapy development. It is one of a few institutions dominating global innovation in the space; more than 400 CAR-T patents and 40 patent families have been registered by UCL alone. The Institute of Child Health, where Dr. Barisa is based, is closely associated with Great Ormond Street Hospital for Children. The hospital, with its associated research institute, is Europe’s biggest and highest-ranked centre for paediatric health, excelling particularly with the quality and quantity of its translational research that is coupled to clinical trials.

Dr. Barisa’s specialism rests with the design, development and translation of genetically-modified adoptive cellular immunotherapies for solid tumours. In this capacity she is based across two different immunotherapy groups at UCL: (i) the Innate Immune Engineering Lab, which is focused on allogeneic, gene-modified γδ T cell therapeutic development for adolescent and adult solid cancers, including carcinoma and sarcoma, and (ii) the Experimental Paediatric Oncology Lab, where she evaluates a range of autologous as well as allogeneic chimeric antigen receptor (CAR-T) αβ and γδ T cell interventions for their ability to target paediatric neuroendocrine tumours.

Throughout her career, she has woven together academic and commercial cell therapy development. She has held roles in both private biotech companies and academic institutions - often building novel cell therapy concepts in the academic space, and then funding the late-stage development of these with commercial partners. She serves on scientific advisory boards and holds patents pertaining to novel cellular immunotherapy designs and manufacturing methodologies. She lectures on cell therapy development regularly, and is a co-lead of a postgraduate programme for Cell & Gene Therapy at UCL.

De la contraportada

?d T Cell Cancer Immunotherapy: Evidence-Based Perspectives for Clinical Translation covers and critically discusses the current pre-clinical and clinical ?d T cell landscape. In 9 chapters it not only focuses on the promises of what’s to come, but also on the challenges faced by the field, as well as suggestions and discussion around potential solutions by experts in the area.

Particular attention is given to summarizing recent advances on what is known about relevant areas of ?d T cell biology on summarizing the ‘big picture’ clinical situation, an up-to-date systematic clinical trial review covering autologous, allogeneic, engineered and non-engineered therapies and perspectives on the types of cutting-edge gene-engineering that may be required to enhance the effect-size and durability of therapeutic efficacy.

Content provides an updated and comprehensive insight into the current state of ?d T cell immunotherapy, providing discussion on the promise as well as challenges of the field that is of interest to existing translational ?d T cell specialists, the proliferating range of academic scientists and commercial scientists entering the field, as well as clinicians who may encounter ?d T cell immunotherapy in the clinic or are wishing to familiarize themselves with non-canonical lymphocyte immunotherapy.